Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
&NA; Serrated adenocarcinoma, an alternative pathway for colorectal cancer (CRC) development, accounts for 15%–30% of all CRCs and is aggressive and treatment resistant. We show that the expression of atypical protein kinase C &zgr; (PKC&zgr;) and PKC&lgr;/&igr; was reduced in human serrated tumors. Simultaneous inactivation of the encoding genes in the mouse intestinal epithelium resulted in spontaneous serrated tumorigenesis that progressed to advanced cancer with a strongly reactive and immunosuppressive stroma. Whereas epithelial PKC&lgr;/&igr; deficiency led to immunogenic cell death and the infiltration of CD8+ T cells, which repressed tumor initiation, PKC&zgr; loss impaired interferon and CD8+ T cell responses, which resulted in tumorigenesis. Combined treatment with a TGF‐&bgr; receptor inhibitor plus anti‐PD‐L1 checkpoint blockade showed synergistic curative activity. Analysis of human samples supported the relevance of these kinases in the immunosurveillance defects of human serrated CRC. These findings provide insight into avenues for the detection and treatment of this poor‐prognosis subtype of CRC. Graphical Abstract Figure. No caption available. HighlightsAtypical protein kinase C (aPKC) expression is reduced in human serrated tumorsDeletion of both aPKCs in intestinal epithelium causes spontaneous serrated tumorsaPKC‐deficient tumors display immunosuppression and stromal activationLoss of PKC&zgr; impairs the CD8+ T cell response, triggering serrated tumor initiation &NA; Serrated adenocarcinomas are an aggressive and treatment‐resistant form of colorectal cancer. Nakanishi et al. show that expression of atypical PKCs is reduced in human serrated tumors and that their loss results in spontaneous serrated tumorigenesis with stromal activation and immunosuppression in mice. The simultaneous inhibition of stromal activation combined with anti‐PD‐L1 showed synergistic therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022 · cited 1×
“DNA methyltransferase inhibitors (DNMTi) have recently been used to transcriptionally upregulate human endogenous activators of the double-stranded RNA sensing pathway that culminates in the stimulation of the type I and III interferon responses (Chiappinelli et al., 2015).”
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Self-citationStromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070 · cited 2×
“One of the characteristics of the advanced PrkciPrkczVillin-cre tumors is a high desmoplastic response, which has been proposed to be critical for CRC progression toward high malignancy (Calon et al., 2015; Isella et al., 2015).”
Self-citationMlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034 · cited 1×
“Although the MSI-high phenotype is associated with serrated tumorigenesis, a significant proportion of poor-prognosis serrated tumors are microsatellite stable (MSS) and respond poorly to single-agent PD-1 inhibitor treatment, yet a subgroup of MSS patients have high PD-1 expression and have been suggested to benefit…”
Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., Ohta, Y., Toshimitsu, K., Nakazato, Y., Kawasaki, K., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.003 · Cited by 852 · cited 4×
“The comparison of these transcriptomic data to recently reported gene signatures generated from human organoids from serrated lesions, tubular or tubulovillous adenoma, and MSI or MSS CRCs (Fujii et al., 2016) demonstrated that genes upregulated in the Prkcifl/flPrkczfl/flVillin-cre tumors positively correlated with t…”
InfluentialDe Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640
Bennecke, M., Kriegl, L., Bajbouj, M., Retzlaff, K., Robine, S., Jung, A., Arkan, M. C., Kirchner, T., & Greten, F. R. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.013 · Cited by 186 · cited 12×
“Moreover, in mouse models, the additional inactivation of tumor suppressors, such as p16, p53, or CDX2, outside of the ERK pathway is required for these tumors to progress to the advanced carcinoma stage (Bennecke et al., 2010; Rad et al., 2013).”
Influential
Cited by
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Self-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Omatsu, M., Nakanishi, Y., Iwane, K., Aoyama, N., Duran, A., Muta, Y., Martinez-Ordoñez, A., Han, Q., Agatsuma, N., Mizukoshi, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41095-y · Cited by 109
Self-citationEquivocal, explicit and emergent actions of PKC isoforms in cancer
Parker, P. J., Brown, S. J., Calleja, V., Chakravarty, P., Cobbaut, M., Linch, M., Marshall, J. J. T., Martini, S., McDonald, N. Q., Soliman, T., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00310-4 · Cited by 65
Metadata
- Authors
- Nakanishi, Y., Duran, A., L’Hermitte, A., Shelton, P. M., Nakanishi, N., Reina-Campos, M., Huang, J., Soldevila, F., Baaten, B. J. G., Tauriello, D. V. F., Castilla, E. A., Bhangoo, M. S., Bao, F., Sigal, D., Diaz-Meco, M. T., & Moscat, J.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 49
- Issue
- 6
- Pages
- 1132-1147.e7
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2905189746
- Cited by
- 60
- References
- 9
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.